About: COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination
Creator	Grigoriadis, Nikolaos Evdoshenko, Evgeniy Kleopatra Boziki, Marina Makshakov, Gleb Mentis, Alexios-Fotios Shumilina, Maria
Source	Medline; PMC; WHO
abstract	In the frame of the coronavirus disease 2019 (COVID-19) pandemic, recent reports on SARS-CoV-2 potential neuroinvasion placed neurologists on increased alertness in order to assess early neurological manifestations and their potentially prognostic value for the COVID-19 disease. Moreover, the management of chronic neurological diseases, such as Multiple Sclerosis (MS), underwent guided modifications, such as an Extended Interval Dose (EID) of Disease-Modifying Treatment (DMT) administration, in order to minimize patients’ exposure to the health system, thus reducing the risk of SARS-CoV-2 infection. In this review, we summarize existing evidence of key immune pathways that the SARS-CoV-2 modifies during COVID-19 and the relevant implication for MS and other autoimmune diseases with associated demyelination (such as Systemic lupus erythematosus and Antiphospholipid syndrome), including the context of potential neuroinvasion by SARS-Cov-2 and the alterations that DMT induces to the immune system. Moreover we hereby aim to provide an overview of the possible consequences that COVID-19 may carry for the Central Nervous System (CNS) in People with MS (PwMS) and other demyelinating diseases, which are likely to pose challenges for treating Neurologists with respect to the long-term disease management of these diseases.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.3390/brainsci10060345
bibo:pmid	32512702
has license	cc-by
sha1sum (hex)	f2712f6f55d4bcfd0835bf6b8ea30e7cee906992
schema:url	https://doi.org/10.3390/brainsci10060345
resource representing a document's title	COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination
has PubMed Central identifier	PMC7349282
has PubMed identifier	32512702
schema:publication	Brain Sci
resource representing a document's body	covid:f2712f6f55d4bcfd0835bf6b8ea30e7cee906992#body_text
is schema:about of	named entity 'key' named entity 'potential' named entity 'Neurologists' named entity 'SARS-Cov-2' named entity 'potential' named entity 'Demyelination' named entity 'CHALLENGES' named entity 'POTENTIAL' named entity 'DISEASES' named entity 'ADMINISTRATION' named entity 'PATIENTS' named entity 'ORDER' named entity 'MULTIPLE SCLEROSIS' named entity 'ANTIPHOSPHOLIPID SYNDROME' named entity 'TREATING' named entity 'MODIFIES' named entity 'REPORTS' named entity 'PEOPLE' named entity 'ASSESS' named entity 'DMT' named entity 'chronic' named entity 'management' named entity 'frame' named entity 'administration' named entity 'coronavirus disease 2019' named entity 'People' named entity 'risk' named entity 'Central Nervous System (CNS)' named entity 'Antiphospholipid syndrome' named entity 'SARS-CoV-2' named entity 'Multiple Sclerosis' named entity 'CNS' named entity 'DMT' named entity 'COVID-19' named entity 'DMT' named entity 'COVID-19' named entity 'inflammation' named entity 'CD8+ T cells' named entity 'SLE' named entity 'COVID' named entity 'neuroinvasive' named entity 'cladribine' named entity 'cognitive function' named entity 'COVID' named entity 'cranial nerves' named entity 'infection' named entity 'ICU' named entity 'SARS-CoV-2 pandemic' named entity 'Disease-Modifying' named entity 'RNA' named entity 'arthralgia' named entity 'stroke' named entity 'urine' named entity 'coronavirus infection' named entity 'COVID' named entity 'thrombocytopenia' named entity 'B-cell' named entity 'general population' named entity 'infection' named entity 'Nausea' named entity 'cerebrospinal fluid' named entity 'comorbidities' named entity 'COVID-19' named entity 'partial thromboplastin time' named entity 'SARS-CoV-2' named entity 'cytokine IL-6' named entity 'COVID' named entity 'human coronaviruses' named entity 'vasoconstriction' named entity 'demyelination' named entity 'CNS' named entity 'hypertension' named entity 'neurodegenerative diseases' named entity 'SARS-CoV-2' named entity 'ARDS' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software